APTIMA HPV 16 18/45 GENOTYPE ASSAY

Kit, Rna Detection, Human Papillomavirus

FDA Premarket Approval P120007

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the aptima hpv 16 18/45 genotype assay. Aptima hpv 16 18/45 genotype assay indications for use:the aptima hpv 16 18/45 genotype assay is an in vitro nucleic acid amplification test for the qualitative detection of e6/e7 viral messenger rna (mrna) of human papillomavirus (hpv) types 16, 18, and 45 in cervical specimens from women with aptima hpv assay positiveresults. The aptima hpv 16 18/45 genotype assay can differentiate hpv 16 from hpv 18 and/or hpv 45, but does not differentiate between hpv 18 and hpv 45. Cervical specimens in thinprep pap test vials containing preservcyt solution and collected with broom-type orcytobrush/spatula collection devices* may be tested with the aptima hpv 16 18/45 genotype assay. The assay is used with the tigris dts system. The use of the test is indicated: 1) in patients 21 years and older with atypical squamous cells of undetermined significance(asc-us) cervical cytology results, the aptima hpv 16 18/45 genotype assay can be used to test samples from women with aptima hpv assay positive results to assess the presence or absence of high-risk hpv genotypes 16, 18, and/or 45. This information, together with the physician's assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management. The results of this test are not intended to prevent women from proceeding to colposcopy; and 2) in women 30 years and older, the aptima hpv 16 18/45 genotype assay can be used to test samples from women with aptima hpv assay positive results. The assay results wi11 be used in combination with cervical cytology to assess the presence or absence of high-risk hpv genotypes 16, 18, and/or 45. This information, together with the physician's assessment of cytology history, other risk factors, and professional guidelines, may be used to guide patient management * broom-type device (e. G. , wallach pipette), or endocervical brush/spatula.

DeviceAPTIMA HPV 16 18/45 GENOTYPE ASSAY
Classification NameKit, Rna Detection, Human Papillomavirus
Generic NameKit, Rna Detection, Human Papillomavirus
ApplicantGEN-PROBE INCORPORATED
Date Received2012-04-19
Decision Date2012-10-12
Notice Date2012-11-01
PMAP120007
SupplementS
Product CodeOYB
Docket Number12M-1066
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address GEN-PROBE INCORPORATED 10210 Genetic Center Drive san Diego, CA 92121
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Post-Approval Study:Show Report Schedule and Study Progress
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P120007Original Filing
S029 2021-12-14 Real-time Process
S028 2020-07-09 30-day Notice
S027 2020-05-14 30-day Notice
S026 2019-12-23 Real-time Process
S025
S024 2019-08-21 30-day Notice
S023 2019-08-02 30-day Notice
S022
S021 2019-03-27 30-day Notice
S020 2019-03-18 Real-time Process
S019 2019-03-01 Real-time Process
S018 2018-12-31 Real-time Process
S017 2018-08-31 30-day Notice
S016 2018-08-16 30-day Notice
S015 2018-03-15 30-day Notice
S014 2018-02-08 30-day Notice
S013 2017-12-20 30-day Notice
S012 2017-10-10 30-day Notice
S011 2017-09-01 Normal 180 Day Track
S010 2017-03-17 Real-time Process
S009 2016-08-15 30-day Notice
S008 2016-03-01 30-day Notice
S007 2015-10-16 30-day Notice
S006 2015-08-28 135 Review Track For 30-day Notice
S005
S004 2015-03-04 30-day Notice
S003 2014-12-24 Normal 180 Day Track No User Fee
S002 2014-04-17 Real-time Process
S001 2013-05-15 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.